阿片类药物及其受体：阿片类药物发现的现状和新兴概念 II。
Opioids and Their Receptors: Present and Emerging Concepts in Opioid Drug Discovery II.
机构信息
Department of Medicinal Chemistry and Molecular Pharmacology, Purdue Institute for Drug Discovery, and Purdue Institute for Integrative Neuroscience, Purdue University, West Lafayette, IN 47907, USA.
Septerna Inc., San Francisco, CA 94080, USA.
出版信息
Molecules. 2022 May 13;27(10):3140. doi: 10.3390/molecules27103140.
Abstract
A few neurotransmitter systems have fascinated the research community, as muchas the opioid system (i.e., opioid ligands and their receptors) [...].
摘要
一些神经递质系统引起了研究界的极大兴趣，就像阿片样系统（即阿片样配体及其受体）一样[... ]。
相似文献
1
Opioids and Their Receptors: Present and Emerging Concepts in Opioid Drug Discovery II.阿片类药物及其受体：阿片类药物发现的现状和新兴概念 II。
Molecules. 2022 May 13;27(10):3140. doi: 10.3390/molecules27103140.
2
Bifunctional opioid receptor ligands as novel analgesics.双功能阿片受体配体作为新型镇痛药。
Neuropharmacology. 2019 Jun;151:195-207. doi: 10.1016/j.neuropharm.2019.03.006. Epub 2019 Mar 8.
3
Opioids and Their Receptors: Present and Emerging Concepts in Opioid Drug Discovery.阿片类药物及其受体：阿片类药物发现中的现有和新兴概念。
Molecules. 2020 Dec 1;25(23):5658. doi: 10.3390/molecules25235658.
4
Structural Insights Accelerate the Discovery of Opioid Alternatives.结构洞察加速阿片类药物替代品的发现。
Annu Rev Biochem. 2021 Jun 20;90:739-761. doi: 10.1146/annurev-biochem-061620-044044. Epub 2021 Mar 23.
5
Opioids.阿片类药物。
Handb Exp Pharmacol. 2007(177):31-63. doi: 10.1007/978-3-540-33823-9_2.
6
Discriminative Stimulus Properties of Opioid Ligands: Progress and Future Directions.阿片类配体的辨别刺激特性：进展与未来方向
Curr Top Behav Neurosci. 2018;39:175-192. doi: 10.1007/7854_2016_9.
7
[Pain inhibition by opioids-new concepts].[阿片类药物的疼痛抑制——新概念]
Anaesthesist. 2019 Feb;68(2):97-103. doi: 10.1007/s00101-018-0528-0.
8
Opioid Receptors.阿片受体。
Annu Rev Med. 2016;67:433-51. doi: 10.1146/annurev-med-062613-093100. Epub 2015 Aug 26.
9
Historical perspectives and recent advances in small molecule ligands of selective/biased/multi-targeted μ/δ/κ opioid receptor (2019-2022).选择性/偏向性/多靶点μ/δ/κ 阿片受体小分子配体的历史观点和最新进展（2019-2022 年）。
Bioorg Chem. 2023 Dec;141:106869. doi: 10.1016/j.bioorg.2023.106869. Epub 2023 Sep 20.
10
Structural Characterization of KOR Inactive and Active States for 3D Pharmacology and Drug Discovery.三维药理学和药物发现中 KOR 无活性和活性状态的结构特征。
Handb Exp Pharmacol. 2022;271:41-64. doi: 10.1007/164_2021_461.
本文引用的文献
1
Non-Peptide Opioids Differ in Effects on Mu-Opioid (MOP) and Serotonin 1A (5-HT) Receptors Heterodimerization and Cellular Effectors (Ca, ERK1/2 and p38) Activation.非肽类阿片样物质对μ-阿片受体（MOP）和血清素 1A 受体（5-HT）异源二聚体及细胞效应器（Ca、ERK1/2 和 p38）激活的影响存在差异。
Molecules. 2022 Apr 6;27(7):2350. doi: 10.3390/molecules27072350.
2
Mechanistic Characterization of the Pharmacological Profile of HS-731, a Peripherally Acting Opioid Analgesic, at the µ-, δ-, κ-Opioid and Nociceptin Receptors.HS-731 作为一种外周作用阿片类镇痛药，在μ-、δ-、κ-阿片受体和孤啡肽受体上的药理学特征的机制研究。
Molecules. 2022 Jan 28;27(3):919. doi: 10.3390/molecules27030919.
3
Spotlight on Nociceptin/Orphanin FQ Receptor in the Treatment of Pain.聚焦于孤啡肽/阿片肽受体在疼痛治疗中的作用。
Molecules. 2022 Jan 18;27(3):595. doi: 10.3390/molecules27030595.
4
An updated assessment of the translational promise of G-protein-biased kappa opioid receptor agonists to treat pain and other indications without debilitating adverse effects.更新评估 G 蛋白偏向性 κ 阿片受体激动剂在治疗疼痛和其他适应症方面的转化潜力，而没有使人衰弱的不良反应。
Pharmacol Res. 2022 Mar;177:106091. doi: 10.1016/j.phrs.2022.106091. Epub 2022 Jan 29.
5
Synthesis, Pharmacological Evaluation, and Computational Studies of Cyclic Opioid Peptidomimetics Containing β-Lysine.含β-赖氨酸的环状阿片肽类似物的合成、药理评价和计算研究。
Molecules. 2021 Dec 28;27(1):151. doi: 10.3390/molecules27010151.
6
Identification of a Novel Delta Opioid Receptor Agonist Chemotype with Potential Negative Allosteric Modulator Capabilities.鉴定具有潜在负变构调节剂能力的新型 δ 阿片受体激动剂化学型。
Molecules. 2021 Nov 29;26(23):7236. doi: 10.3390/molecules26237236.
7
Characterization of the Synergistic Effect between Ligands of Opioid and Free Fatty Acid Receptors in the Mouse Model of Colitis.在结肠炎小鼠模型中鉴定阿片和游离脂肪酸受体配体的协同作用。
Molecules. 2021 Nov 11;26(22):6827. doi: 10.3390/molecules26226827.
8
Discovery of Novel Delta Opioid Receptor (DOR) Inverse Agonist and Irreversible (Non-Competitive) Antagonists.新型 δ 阿片受体（DOR）反向激动剂和不可逆（非竞争性）拮抗剂的发现。
Molecules. 2021 Nov 5;26(21):6693. doi: 10.3390/molecules26216693.
9
Shedding Light on the Pharmacological Interactions between μ-Opioid Analgesics and Angiotensin Receptor Modulators: A New Option for Treating Chronic Pain.揭示 μ 阿片类镇痛药与血管紧张素受体调节剂之间的药理学相互作用：治疗慢性疼痛的新选择。
Molecules. 2021 Oct 13;26(20):6168. doi: 10.3390/molecules26206168.
10
Difelikefalin: First Approval.地氟烷：首次批准。
Drugs. 2021 Nov;81(16):1937-1944. doi: 10.1007/s40265-021-01619-6.
Zotero 插件